Literature DB >> 24228532

[Multi-centered, randomized controlled clinical study on Chinese medicine formula particles for hyperlipidaemia associated with highly active antiretroviral therapy].

Liang Ni1, Rong-Bing Wang, Hui-Jun Guo, Xing-Hua Tan, Li-Jun Sun, Yu-Huang Zheng, Cheng-Yu Duan, Da-Qing Hu, Wen-Jing Wang, Yu-Guang Wang, Hong-Xin Zhao.   

Abstract

OBJECTIVE: To observe the effect and safety of Xiaozhi particles, integrated taohong Siwu tang and Erchen tang and Xuezhikang capsule in treating hyperlipidaemia (HLP) associated with highly active antiretroviral therapy (HAART).
METHOD: In the multi-centered, randomized controlled clinical study, 180 hyperlipidaemia associated with highly active antiretroviral therapy cases were divided into the treatment group treated by Xiaozhi particles, integrated Taohong Siwu tang and Erchen tang, and the control group treated by Xuezhikang capsule. The treatment course was 12 weeks. The total cholesterol (Tch), triglyceride (TG), low density lipoprotein (LDL) and high-density lipoprotein(HDL) were observed. RESULT: After 12 weeks, compared with Xuezhikang capsule, the change difference of Tch, LDL, HDL in the Chinese traditional medicine formula groups of patients is significant (P < 0.05), the change of the TG has no significant difference. The effect of Tch, LDL in Xuezhikang capsule groups is better than in traditional Chinese medicine formula group,but the effect of HDL in traditional Chinese medicine formula group is better than in Xuezhikang capsule groups.
CONCLUSION: Integrated Taohong Siwu tang and Erchen tang, Xiaozhi particles and Xuezhikang capsule can be used to control the hyperlipidaemia associated with highly active antiretroviral therapy as one of the main Chinese native medicine preparation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24228532

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.

Authors:  Rui-Xia Xu; Yan Zhang; Yuan-Lin Guo; Chun-Yan Ma; Yu-Hong Yao; Sha Li; Xiao-Lin Li; Ping Qing; Ying Gao; Na-Qiong Wu; Cheng-Gang Zhu; Geng Liu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Chronic Dis Transl Med       Date:  2017-11-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.